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Abstract: A stereodivergent strategy to obtain enantiopure cis and 
trans 4-aminopipecolic acids (4-APAs) in a suitably protected form 
for peptide synthesis has been devised starting from a common, 
known precursor in turn easily prepared from commercial (R)-4-
cyano-3-hydroxybutyric acid ethyl ester. The two isomers were 
efficiently obtained in 40% and 23% overall yields, respectively, in 
seven and ten steps. To demonstrate their usefulness in 
peptidomimetic synthesis, both 4-APA isomers were incorporated as 
γ-amino acid in a cyclic RGD-containing sequence, although for the 
trans 4-APA isomer a further amino acid in the sequence (L-Phe) 
was needed to allow ring closure. The two cyclopeptides were tested 
as αVβ3 integrin antagonists in comparison with cilengitide. 
Introduction 
Cis and trans 4-aminopipecolic acids 1 and 2 (Figure 1, a) are 
endocyclic-Nα/exocyclic-Nγ-constrained, naturally occurring[1] 
basic amino acids with great potential in medicinal chemistry not 
only as α-amino acids with restricted φ, χ1, χ2, and/or χ3 torsion 
angles, but also as rigid γ-amino acids. Surprisingly, only few 
examples of peptidomimetics incorporating 4-aminopipecolic 
acids as either α- or γ-amino acids exist, or synthetic bioactive 
compounds embedding them.[2] Also, a very limited number of 
stereoselective synthesis of compounds 1 and 2 have been 
reported, often leading to mixtures of isomers or compounds 
with unsuitable protection for peptide synthesis.[2b, 3] The most 
efficient strategies for the synthesis of both cis and trans 4-APAs 
make use of commercially available, but very expensive, N-Boc 
protected cis 4-hydroxypipecolic acid.[2b,3a] Since we had 
reported, a few years ago, on efficient chemical and chemo-
enzymatic syntheses of cis 4-hydroxy pipecolic acids,[4] we 
decided to exploit our previous knowledge to perform a 
stereodivergent, enantioselective synthesis of 4-aminopipecolic 
acids and to demonstrate their usefulness in the preparation of 
peptidomimetics. In particular, we wanted to use them as 
conformationally constrained γ-amino acids for the preparation of 
cyclic RGD-containing peptidomimetics as antagonists of αVβ3 
integrin receptor. This integrin is a heterodimeric 
transmembrane receptor for extracellular matrix (ECM) proteins 
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Figure 1. (a) Cis and trans 4-aminopipecolic acids 1 and 2, and the target αVβ3 
integrin ligands. (b) Hydroxy- and aminopipecolic acid derivatives, and 4-
aminoproline. 
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The αVβ3 integrin receptor, which recognizes the RGD sequence 
of vitronectin,[6] has a critical role in tumor-induced angiogenesis 
and metastasis formation.[7] Therefore, RGD-containing peptides 
and peptidomimetics[8] as well as RGD mimetics[5a] are currently 
evaluated as antagonists to suppress the events mediated by 
this integrin and as possible shuttles for the targeted delivery of 
drugs and diagnostics.[7b, 9] In line with this, we have recently 
reported that pipecolic acid derivatives such 4- and 5-
aminocyclopropane pipecolic acids,[10] 4-hydroxycyclopropane 
pipecolic acids,[11] and 5-aminopipecolic acids[12] are all suitable, 
rigid amino acids on which to build the RGD sequence to obtain 
highly active αVβ3 integrin receptor antagonists (Figure 1, b). 
These aminopipecolic acid derivatives are homologous of 4-
aminoproline (Figure 1), a derivative of 4-hydroxyproline which 
has been extensively exploited in the last decade for the 
generation of αVβ3 integrin ligands and drug conjugates.
[8h,i],[9f-h] 
As a completion of our studies on pipecolic acid derivatives,[4, 10-
12,13] in this paper we wish to report on our efforts to prepare 
orthogonally protected cis and trans 4-aminopipecolic acids 
suitable for peptide synthesis and their use in the construction of 
RGD peptidomimetics as integrin antagonists.  
 
Results and Discussion 
Having identified in cis 4-hydroxypipecolic acid the key 
intermediate for the synthesis of both cis and trans 4-
aminopipecolic acids, we decided to prepare its N-CO2Me 
protected form 7 (Scheme 1) from commercially available (R)-3 
as we have previously reported.[4b] However, some unexpected 
complications arose when repeating that sequence on a larger 
scale (15 mmol) and further experimentation was thus required 
to have a reliable and robust methodology in hand. So, while the 
transformation of (R)-3 into α,β-unsaturated ester 4 proceeded 
smoothly as reported,[4b] the hydrogenation of the latter under the 
original (wet 10% Pd/C in EtOAc) conditions caused the almost 
total loss of the t-butoxy group to form 6. This was reasonably 
due to the proneness of 4 to form an allylic cationic species, fully 
conjugated with the nitrogen atom, upon protonation of the t-
butoxy oxygen atom under acid/aqueous conditions. Only by 
using dry 10% Pd/C in anhydrous THF, i.e. having care to 
remove water and any acid source from the reaction medium, 
the reaction provided diastereopure cis 5 quantitatively, with just 
a low content of the unwanted byproduct. Deprotection of the 4-
OH group was first attempted with pTsOH in acetonitrile, but this 
caused epimerization at C2 and partial formation of lactone 8. In 
the next attempt with TFA in dichloromethane at room 
temperature, quantitative formation of lactone 8 was 
observed.[14] However, we were glad to find that by carrying out 
this reaction at 0 °C, only desired alcohol 7 was obtained in 69% 
yield. Simple functional group manipulation then allowed us to 
convert this cis 4-hydroxypipecolic acid derivative into target N-
Fmoc-protected trans 4-aminopipecolic acid 14. The only 
problem we encountered was the partial elimination from 
mesylate 9 to form, after double bond migration, α,β-unsaturated 
ester 11 when we carried out the nucleophilic displacement by 


































































Scheme 1. Synthesis of Fmoc-protected trans 4-APA 14. (a) H2, 10% Pd/C, 
THF, 24 h (100%); (b) TFA, DCM, 0 °C, 4 h (69%); (c) MsCl, Et3N, DCM, -30 
to 25 °C, 2 h (92%); (d) NaN3, DMF, 100 °C, 3 h (80%); (e) 1N NaOH, MeOH, 
2 h (100%); (f) H2, 10% Pd/C, MeOH, 24 h (100%); (g) FmocOSu, 10% aq. 
Na2CO3, THF, 0 to 25 °C, 19 h (79%). 
For the synthesis of the corresponding cis 4-APA (Scheme 2) 
from alcohol 7, we first carried out a Mitsunobu reaction to invert 
the configuration at C4. However the reaction provided acetate 
15 in low yield and in impure form. After deprotection and 
mesylation of the OH group, nucleophilic substitution by NaN3 
occurred smoothly to form 18. No elimination products were 
observed as in this case the leaving group in 17 is equatorially 
oriented.[15] Unfortunately, when we tried to hydrolyze the ester 
under alkaline conditions, epimerization to form a mixture of cis 
and trans 19 was unavoidable, despite some precedents in 
literature on analogous systems in which epimerization was not 
reported.[3a] We therefore changed approach and a different way 
to obtain the free carboxylic acid was attempted. So, after 
exhaustive hydrolysis of 7[4b] followed by N-Boc protection, 
compound 21 was protected as benzyl ester 22 (Scheme 3). 
The OH group was then converted into a leaving group and 23 
finally treated with LiBr in dry DMF to perform the first inversion 
of configuration.[3a] In this case also, in contrast to what has 
been reported,[3a] we observed the formation of a 7.3 : 1 mixture 
of desired trans compound 24 and elimination products 25. 
Treatment of this mixture with NaN3 in DMF at 70 °C generated 
cis azide 26 together with α,β-unsaturated ester 27, the latter 
deriving from both isomerization of 25 and elimination from azide 
26 (in which the azide group is axially oriented).[15] Eventually, 
hydrogenation of the azide group with concurrent deprotection of 
the carboxylic group, followed by N-Fmoc protection, allowed us 
to obtain orthogonally protected cis 4-APA 29 which, however, 
could be only partially separated by chromatography on silica 
gel from the by-products formed in the previous steps of the 
synthesis.[16] 










































Scheme 2. Attempt at preparing cis 4-APA. (a) DIAD, Ph3P, AcOH, THF, 0 °C, 
4 h; (b) MeONa, MeOH, 0 °C, 6 h (33%, two steps); (c) MsCl, Et3N, DCM, -30 
to 25 °C (100 %); (d) NaN3, DMF, 100 °C, 3 h (81%); (e) 1N NaOH, MeOH, 






















































Scheme 3. Synthesis of Fmoc-protected cis 4-APA 29. (a) 2N HCl, reflux, 21 h 
(100%); (b) Boc2O, Et3N, MeOH, reflux, 21 h (100%); (c) BnBr, K2CO3, DMF, 0 
to 25 °C, 24 h (89%); (d) MsCl, Et3N, DCM, -30 to 25 °C (100%); (e) LiBr, DMF, 
70 °C, 2 d (48%); (f) NaN3, DMF, 70 °C, 22 h (98%); (g) H2, 10% Pd/C, MeOH, 
4.5 h (100%); (h) FmocOSu, 10% aq. Na2CO3, THF, 0 to 25 °C, 19 h (78%). 
Both trans and cis 4-APA 14 and 29, respectively, were then 
incorporated into cyclopeptides bearing the RGD (Arg-Gly-Asp) 
sequence recognized by the αVβ3 integrin (Schemes 4 and 5). 
Due to the trans stereochemistry of 4-APA 14, and the C-C bond 
at C2 being axially oriented,[15] we needed to embody a further 
amino acid into the sequence to allow the final ring closure. The 
results of a preliminary molecular modeling study (vide infra) 
resulted in L-Phe as the best amino acid to insert between 4-
APA and the aspartate in order to match the binding 
conformation of cilengitide.[17] Thus, our trans 4-APA was 
coupled to the suitably protected dipeptide H-Arg(Mtr)-Gly-OBn 
to form 30 (86%), using DEPBT [3-(diethoxyphosphoryloxy)-
1,2,3-benzotriazin-4(3H)-one] as the coupling reagent in THF at 
35 °C (Scheme 4). After deprotection of the amino group at C4, 
compound 31 was coupled to the Z-Asp(OtBu)-Phe-OH 
dipeptide under the above conditions to obtain 32 in excellent 
yield. This was subjected to hydrogenation to quantitatively form 
33 which was in turn treated with DEPBT in a very dilute solution 
to attain cyclization. The reaction was stopped after 4 days and 
the cyclopeptide purified by semi-preparative HPLC providing 
compound 34 in pure form but in very low yield (11%). This is 
due to the many by-products formed during the last step. Indeed, 
despite lengthening one of the reacting arms with L-Phe, the 
trans nature of the 4-APA scaffold made cyclization very difficult.  
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Scheme 4. Synthesis of cyclopeptide 34. (a) DEPBT, DIPEA, H-Arg(Mtr)-Gly-
OBn, THF, 35 °C, 4 d (86%); (b) CH2Cl2/DEA 1:1, 3 h (100%); (c) DEPBT, 
DIPEA, Z-Asp(OtBu)-Phe-OH, THF, 35 °C, 4 d (98%); (d) H2 (1 atm), 10% 
Pd/C, EtOH, 24 h (100%); (e) DEPBT, DIPEA, THF, 35 °C, 4 d (59%); (f) 
TFA/TIS/H2O 95:2.5:2.5, 18 h (11%). 
By an analogous synthetic approach, we converted cis 4-APA 
29 into a cyclopeptide bearing the RGD sequence. Obviously, in 
this case we did not need a further amino acid into the sequence 
to facilitate cyclization. So (Scheme 5), after formation and 
deprotection of tripeptide 35 (which we could not purify properly) 
to generate 36, the free amino group was reacted with the 
suitably protected aspartic acid to give 37 in 77% yield. After 
hydrogenation, cyclization and eventual exhaustive deprotection, 
cyclopeptide 39 was obtained in 24% after semi-preparative 
HPLC purification.  
Cyclopeptides 34 and 39 were fully characterized by combining 
mono- and bi-dimensional homonuclear (1H) experiments 
[proton, variable temperature (VT), gCOSY, and NOESY 
experiments in aqueous solution (D2O/H2O 1:9) and molecular 
modeling. 

















































































Scheme 5. Synthesis of cyclopeptide 39. (a) DEPBT, DIPEA, H-Arg(Mtr)-Gly-
OBn, THF, 35 °C, 4 d (93%); (b) CH2Cl2/DEA 1:1, 4 h (100%); (c) DEPBT, 
DIPEA, Z-Asp(OtBu)-OH, THF, 35 °C, 4 d (77%); (d) H2 (1 atm), 10% Pd/C, 
EtOH, 24 h (100%); (e) DEPBT, DIPEA, THF, 35 °C, 4 d (50%); (f) 
TFA/TIS/H2O 95:2.5:2.5, 18 h (24%). 
For cyclopeptide 34, 1H NMR analysis revealed the presence of 
two sets of signals in a 1.4 : 1 ratio that are compatible with the 
existence of rotamers at the N-CO2Me bond. As expected, our 
data seem to exclude the existence of a preferred conformation 
for compound 34. The temperature coefficient values comprised 
between −5.4 and −8.0 ppb K−1 (Fig. S1, ESI) for the N–H 
protons of Phe, Asp, Arg and Gly indicate that none of these 
protons is locked in an intramolecular H-bonded state, and the 
analysis of the NOE contacts (Figure 2a) only showed the 
presence of medium–strong sequential CHα(i)/NH(i + 1) 
crosspeaks along the 4-APA-Arg-Gly-Asp-Phe sequence. The 
conformational analysis of compound 34 was also done in silico 
by temperature replica exchange molecular dynamics (T-
REMD),[18] using a protocol that previously proved to be 
successful for similar questions.[11-12,19] Thus, 12 replica of 400 
ns were performed with temperatures ranging from 300 to 860 K, 
without applying any restraint derived from the experimental 
NOEs. This resulted in three structures (c0, c1 and c2) with 
significant populations (49%, 33%, and 13%, respectively) 
(Figure 3) in each of which atomic distances are such to justify 










































































Figure 2. Selected experimental NOEs for compounds 34 and 39. 
For example, in c0 the distance between 4-APA NH and Phe 
CHα (3.6 Å) and between Phe NH and Asp CHα (3.6 Å) are not 
consistent with the observed NOEs. In c1 and c2,  however, all 
distances are consistent with the observed NOEs with the 
exception of those between Phe NH and Asp CHα in c1 (3.8 Å)  
and between 4-APA NH and Phe CHα in c2 (3.5 Å). This could 
be explained by the existence of an equilibrium between these 
three conformations. 




Figure 3. Representative conformations of the main clusters of compound 34. Distances that are relevant to NOE experiments are reported in Å. Values of 
selected dihedrals are shown in Table 1. 
In terms of backbone atom RMSD (Table 1), c0-c2 structures 
match quite well that of cilengitide as measured in the X-ray 
structure of the αVβ3–cilengitide complex.
[20] As suggested by our 
preliminary calculations, the benzyl group of the L-Phe of 34 
overlaps quite well with that of D-Phe in cilengitide, although in 
c0 and c2 geometries only (Figure S2, ESI). Compared to 
cilengitide, relevant differences are observed in the orientation of 
some of the C=O and NH groups of the RGD moiety, as can 
also be evinced by the analysis of the corresponding φ and ψ 
dihedrals (Table 1, Figures 3 and S2, ESI). In particular, the c0 
geometry shows quite divergent ψ1 and φ2 dihedrals, involving 
Arg and Gly, as well as ψ3, involving Asp. The other dihedrals, 
however, are of the same sign as observed in cilengitide. 
Concerning c1, a better match is observed for all RGD dihedrals, 
except ψ3 which shows the opposite sign as in cilengitide. 
Interestingly, the least populated c2 shows a good match for all 
RGD dihedrals. Because of its importance for the biological 
activity, we also compared the distance between the Cβ atoms 
of Asp and Arg. As shown in Table 1, this distance is 
comparable to that measured for bound cilengitide,[20] even if, for 
this parameter also, the best match is obtained for c2. 
A different behavior was instead observed for cyclopeptide 39. 
The NOE contacts (Figure 2b) and the temperature coefficient 
values (Figure S1, ESI), especially those of Asp NH (-4 ppb K−1) 
and 4-APA NH (-3.4 ppb K−1), suggest the existence of a 
preferred and more rigid conformation. REMD simulations 
confirmed experimental data, where the clustering of the 300 K 
trajectory provided a highly populated principal cluster (c0, 87%; 
Figure 4). Additionally, all distances measured on the 
representative conformation of c0 are consistent with the NOEs 
found. For example, the NOE crosspeaks between 4-APA NH 
and axial 6-H (d = 1.9 Å), and between Arg NH and equatorial 3-
H (2.8 Å), are consistent with an optimal orientation of the 4-APA 
NH and Arg CO bond to form a γ-turn. The RMSD between the 
backbone atoms of 39 c0 and cilengitide is as low as 1.0 Å 
(Table 1) and all selected dihedrals match well those of the 
bounded cilengitide. 
Table 1. Selected geometrical parameters (distances in Å, dihedrals in deg.) 
of compound 34 (clusters c0, c1 and c2; Figure 3) and 39 (c0; Figure 4). The 
same parameters are measured in the X-ray of αVβ3–Cilengitide complex for 
comparison. 
  34  39 Cilengitide 
 c0 c1 c2 c0  
Dist. CβArg-CβAsp 9.7 9.5 9.4 8.1 8.9 
RMSDa 1.3 1.1 1.2 1.0 ― 
dih1b 85.9 152.9 72.1 −149.6 ― 
dih2b 159.8 −167.2 149.2 141.7 ― 
φ1 −119.9 −151.1 −126.3 −63.9 −114.5 
ψ1 48.5 93.1 76.8 115.4 130.5 
φ2 −170.5 142.9 148.4 87.0 84.0 
ψ2 −136.1 −145.3 −124.5 −77.2 −136.2 
φ3 −45.5 −62.4 −71.2 −141.0 −87.1 
ψ3 −54.1 −55.7 135.1 97.3 61.4 
φ4  −103.4 −87.0 58.4 ― 172.1 
ψ4 −70.4 158.9 −80.0 ― −122.7 
[a] aRoot mean squared displacement (Å) of backbone atoms of selected 
geometries compared to cilengitide. [b] The C5-C4-N-C=O(Phe) (dih1) and 
N1-C2-C(=O)-N(Arg) (dih2) dihedrals were considered. 
Moreover, the CβArg-CβAsp distance (8.1 Å) results close to that 
observed for cilengitide (8.9 Å) and shorter than in 34 c0-c2 (9.4 
– 9.7 Å). 




Figure 4. Representative conformation of the main cluster of compound 39.  
Distances that are relevant to NOE experiments are reported in Å. Values of 
selected dihedrals are shown in Table 1. 
The greater rigidity of cyclopeptide 39 compared to 34 can be 
explained by the shorter amino acid sequence (three instead of 
four amino acids) grafted onto the cis 4-APA scaffold with the 
two C2-CO and C4-N bonds bearing the RGD sequence being 
axially oriented. Additionally, 39 is likewise stabilized by two γ-
turns involving Asp NH and Arg C=O (d1 = 2.6 Å) and 4-APA NH 
and 4-APA C=O (d2 = 2.5 Å). 
Taken together, these data are in accordance with the inhibition 
activity of 34 (34.73 ± 10.62 µM) and 39 (1.15 ± 0.93 µM) 
relative to that of cilengitide (0.166 ± 0.08 µM) measured on 
WM266-4 metastatic human melanoma cell line overexpressing 
high levels of αVβ3 integrin (Figures S3 and S4, Supporting 
Information).[21, 22]  Cyclopeptide 34 is about 200 times less active 
than cilengitide, this difference in potency likely being due to the 
energy required to switch from the preferred conformation in 
solution to the one that actually bind the receptor. It should be 
reminded that the same simulation protocol was also applied to 
cilengitide itself and that a very good match between the 
preferred conformation in solution and the bounded crystal 
structure was obtained.[17] In case of cyclopeptide 39, its greater 
rigidity and better superposition with cilengitide accounts for it 
being only seven time less active than the latter. 
Conclusion 
In conclusion, a stereodivergent strategy to obtain enantiopure 
cis and trans 4-aminopipecolic acids (4-APAs) in a suitably 
protected form for peptide synthesis has been devised starting 
from a common known precursor (4), in turn easily prepared 
commercial (R)-4-cyano-3-hydroxybutyric acid ethyl ester. The 
two isomers were efficiently obtained in 40% and 23% overall 
yields, respectively, in seven and 10 steps. Both enantiomers of 
cis and trans 4-aminopipecolic acid can in principle be prepared 
given the commercial availability of both enantiomers of the 
starting material. To demonstrate their usefulness in 
peptidomimetics, both isomers were incorporated as y-amino 
acid in a cyclic RGD-containing sequence, although for the trans 
4-APA isomer a further amino acid in the sequence (L-Phe) was 
needed to allow ring closure. The two cyclopeptides were tested 
as αVβ3 integrin antagonist in comparison with cilengitide, which 
resulted only seven times more potent than cyclopeptide 39 
deriving from cis 4-APA isomer and 200 times more potent than 
cyclopeptide 34 deriving from trans 4-APA isomer. The 
difference in potency between the two cyclopeptides can be 
explained by the higher molecular flexibility of cyclopeptide 34 
compared to 39 and the better match of the latter with cilengitide 
in terms of backbone atoms and dihedrals. Further biological 
studies on compound 39 are being carried out and will be 
reported in due course. 
Experimental Section 
Calculations 
Parameterization of trans- and cis-4-APA. Charge parameterization of 
trans 4-APA (as N1-methyl carbamate) and cis-4-APA (unprotected and 
protonated at N1) was performed using the R.E.D. software.[23] Both 
amino acids were capped by an acetyl and a NHMe at the 4-amino and 
at the C2 carboxy groups, respectively. A conformational search was 
then performed using the low mode molecular dynamics the MMFF94x 
force field, and the Born solvation model implemented in MOE,[24] and 
keeping the other parameters to default settings. Two low-energy 
conformations (the first and the third conformation for trans-4-APA, 
having opposite configuration of the tertiary amide group and different 
orientation of the acetylamido group at C4, and the first and fourth 
conformation for cis-4-APA, differing in dih1 and dih2 dihedrals, 
according to Figure Q) were used for charge parameterization. For each 
conformation, two different orientations were used to derive RESP 
charges. Quantum mechanical calculations were performed with 
Gaussian09[25] at the HF/6-31G* level, as requested by the force field. 
REMD simulations. The starting conformations of compounds 34 and 39 
were generated by a conformational search performed with MOE.[24] 
REMD simulations [were performed using the ff96 force field[26] coupled 
with the GB-OBC(II) solvent model[27] according to a protocol previously 
applied to similar synthetic peptides.[11, 12, 19a] The protocol was applied as 
described previously.[12] To evaluate convergence, the 300 K trajectories 
were subjected to a cluster analysis every 100 ns. Convergence was 
considered achieved after 300 ns of simulation, when the population of 
the three principal clusters in consecutive 100 ns batches differed by no 
more than 10%. REMD calculations were performed with  
pmemd.cuda,[28] while cpptraj.cuda executable was used for trajectory 
analyses.[29] Ten clusters were requested for clustering analysis, using 
the average-linkage algorithm, the pairwise mass-weighted RMSD on 
backbone heavy atoms as a metric and sampling one frame per 
picosecond. 
Biological Tests 
Expression of integrin receptors. Tumor cells were detached by gentle 
treatment with Accutase, washed, and incubated for 1 h at 4 °C in the 
presence of monoclonal antibody against different integrin receptors (1 
µg each/50 µL PBS). We used anti-integrin αVβ3-FITC conjugated (11-
0519-42 Thermofisher) and anti-αVβ5 monoclonal antibody (sc13588 
Santa Cruz) followed by incubation with 1 µl/50 µl PBS of goat anti-
mouse IgG FITC-conjugated (22549913 Immunotools) secondary 
antibody. Cells were analyzed at flow cytometer system (FACS Canto II 
Becton&Dickinson). 
Inhibition of melanoma cell adhesion to RGD substrata. Highly 
expressing αVβ3 WM266.4 human melanoma cells were used for 
inhibition of adhesion experiments. 96 wells plates were coated overnight, 
at 4°C, with vitronectin (5 µg/mL) (140-09 Peprotech) or osteopontin (2 
µg/mL 120-35 Peprotech). Plates were, then, washed with Phosphate 
Buffered Saline (PBS) solution and incubated at 37 °C for 1 h with PBS 
containing 1% Bovine Serum Albumin (BSA, A7906 Sigma). WM266.4 
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cells were centrifugated (RT, at 800g) in PBS, to remove serum, counted 
and suspended in serum-free medium at 7.0×105 cells/mL. Melanoma 
cell suspensions were pre-incubated with different amounts of the tested 
compounds (final concentration ranged from 30 µM to 1 nM) at 37 °C for 
30 min to allow the ligand-receptor equilibrium to be reached. Next, cells 
were plated on RGD-containing substrata (6-7×104 cells/well in 200µl 
volume) and incubated at 37 °C for 1 h. The assays were conducted in 
the presence of 2 mmol/L MnCl2.
[9f] At the end of the incubation, plates 
were washed with PBS to remove the non-adherent cells, and 200 µL of 
0.5% crystal violet solution in 20% methanol were added. After 2 h of 
static incubation at 4 °C, plates were examined at 540 nm in a counter 
ELX800 (Bio TEK Instruments). Experiments were done in triplicate and 
repeated at least three times. The values are expressed as % inhibition ± 
SEM of cell adhesion relative to cells exposed to vehicle alone (PBS). 
IC50 values of the tested compounds were calculated using the online 
tool Quest Graph™ IC50 Calculator (AAT Bioquest, Inc., Sunnyvale, CA, 
USA) [IC50 Calculator AAT Bioquest. Available online: 
https://www.aatbio.com/tools/ic50-calculator (accessed on 5 December 
2019)]. 
Chemistry 
Anhydrous solvents were prepared accordingly to the standard 
techniques. Commercially available reagents were used without further 
purification. Melting points were recorded on a Büchi B-540 apparatus 
and are uncorrected. Chromatographic separations were performed 
under pressure on silica gel (Merck 70-230 mesh) by using flash column 
techniques; Rf values refer to TLC carried out on 0.25 mm silica gel 
plates (F254) with the same eluent as indicated for column 
chromatography. 1H NMR (400, 500 MHz) and 13C NMR (100.4 MHz) 
spectra were recorded either on a Bruker Avance II 500 MHz Ultrashield 
or on Varian Inova and Mercury (400 MHz) spectrometers in the 
specified deuterated solvent at 25 °C. Solvent reference lines were set at 
7.26 and 77.00 (CDCl3), 3.31 and 49.00 (CD3OD) in 
1H and 13C NMR 
spectra, respectively. Mass spectra were carried out by direct inlet of a 
10 ppm solution in CH3OH on a LCQ FleetTM Ion Trap LC/MS system 
(Thermo Fisher Scientific) with electrospray ionization (ESI) interface in 
the positive ion mode. HRMS analyses were performed under conditions 
of ESI-MS through direct infusion of a 1 uM solution in MeOH in a 
TripleTOF® 5600+ mass spectrometer (Sciex, Framingham, MA, U.S.A.), 
equipped with a DuoSpray® interface operating with an ESI probe. 
Optical rotations were determined with a JASCO DIP-370 instrument. 
HPLC analyses were performed on a Dionex Acclaim 120, C18, 5 µm, 
4.6-250 mm reverse-phase analytical column at a flow rate of 1 mL min-1 
and using water–acetonitrile gradient eluent buffered with 0.1% TFA. 
Purifications of a small sample of 29 and of cyclopeptides 34 and 39 
were carried out by semi-preparative HPLC using a Dionex Ulltimate 
3000 system equipped with a Alltech Alltima C18, 10 µm, 250 mm × 10 
mm, reverse-phase column, using a water–acetonitrile gradient eluent 
buffered with 0.1% TFA and at a flow rate of 5 mL min-1. Signals were 
monitored at 223 nm with a UV-detector. Compound 4 was synthesized 
as reported.[4b] 
Dimethyl (2S,4R)-4-tert-Butoxypiperidine-1,2-dicarboxylate (5): To a 
stirred suspension of NaHCO3 (242 mg) in anhydrous THF (30.3 mL) was 
added 10% Pd/C (198 mg) under nitrogen atmosphere. The mixture was 
flushed with H2 and then stirring was continued for 30 min. The solution 
of 4 (315 mg) in anhydrous THF (2.8 mL) was added via microsyringe 
and the suspension was stirred at room temperature overnight under 
static H2 pressure. After filtration through a Celite layer and evaporation 
of the solvent, compound 5 (319 mg, 100%) was obtained as a 10:1 
mixture (colourless oil) with the elimination product 6 and it was directly 
used in the next step. Analytical and spectroscopic data are identical to 
those reported in literature.[4b] 
Dimethyl (2S,4R)-4-Hydroxypiperidine-1,2-dicarboxylate (7): 
Compound 5 (319 mg) was dissolved in anhydrous CH2Cl2 (6.9 mL) 
under nitrogen atmosphere and cooled to 0 °C in an ice bath. TFA (1.22 
mL, 15% vol/vol) was added dropwise and the solution was stirred for 4 h 
at 0 °C under nitrogen pressure. Solution was then poured into water (15 
mL) and neutralized by slow addition of saturated aqueous sodium 
bicarbonate and then of solid sodium bicarbonate. The resulting mixture 
was extracted with CH2Cl2 (4 × 15 mL) and the combined organic layers 
were dried over Na2SO4, filtered and evaporated under reduced 
pressure. The crude residue was purified by flash chromatography (n-
hexane-EtOAc, 1 : 2; Rf  0.30) to afford pure 7 (175 mg, 69%) as a 
colourless oil. Analytical and spectroscopic data are identical to those 
reported in literature.[4b] 
(1S,5R)-7-Oxo-6-oxa-2-aza-bicyclo[3.2.1]octane-2-carboxylic acid 
methyl ester (8): Compound 5 (354 mg) was dissolved in anhydrous 
CH2Cl2 (7.6 mL) under nitrogen atmosphere. TFA (1.34 mL, 15% vol/vol) 
was added dropwise and the solution was stirred for 22 h at room 
temperature, under nitrogen pressure. Solution was then poured into 
water (15 mL) and neutralized by slow addition of saturated aqueous 
sodium bicarbonate before and directly of sodium bicarbonate after. The 
resulting mixture was extracted with CH2Cl2 (4 × 15 mL) and the 
combined organic layers were dried over Na2SO4, filtered and 
evaporated under reduced pressure. The crude residue (which was a 
1.6:1 mixture with the alcohol 7) was purified by flash chromatography (n-
hexane-EtOAc, 1 : 2; Rf  0.45) to afford pure 8 (87 mg, 38%) as a 
colourless oil. [α]D
22 ̶ 15.5 (c 0.5, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 
(ppm): 4.97 (t, J = 4.8 Hz, 1 H), 4.91 – 4.64 (m, 1 H), 4.20 – 3.97 (m, 1 H), 
3.72 (s, 3 H), 3.31 – 3.15 (m, 1 H), 2.36 – 2.25 (m, 1 H), 2.12 – 2.00 (m, 
1 H), 1.95 (d, J = 12.0 Hz, 1 H), 1.93 – 1.84 (m, 1 H). 13C NMR (100.4 
MHz, CDCl3) δ (ppm): 172.9, 155.0, 76.8, 53.5, 53.1, 38.5, 36.6, 28.5. 
MS (ESI) m/z (%): 208 ([M + Na]+, 100), 393 ([2M + Na]+, 29). HRMS 
(ESI/TOF) m/z: [M + H]+ Calcd. for C8H11NO4: 186.0761. Found: 
186.0781.[4b] 
Dimethyl (–)-(2S,4S)-4-Methanesulfonyloxypiperidine-1,2-
dicarboxylate (9): Methanesulfonyl chloride (192 µL, 2.48 mmol) was 
added dropwise to a solution of 7 (415 mg, 1.91 mmol) and 
trimethylamine (346 µL, 2.48 mmol) in anhydrous CH2Cl2 (20.1 mL), 
cooled to -30 °C and under nitrogen atmosphere. After 5 min, the cooling 
bath was removed and the reaction mixture was stirred for 2 h at room 
temperature. Water (12 mL) was added, followed by a dropwise addition 
of a 0.5 N solution of HCl (6.7 mL) and, after 10 min, the product was 
extracted with CH2Cl2 (3 × 17 mL). The combined organic layers were 
purified by flash chromatography (n-hexane-EtOAc, 4 : 5; Rf  0.20) to 
afford compound 9 (520 mg, 92%) as a colourless oil. [α]D
18  –11.4 (c 1.0, 
CHCl3). 
1H NMR (400 MHz, CDCl3) (1.4 : 1 mixture of rotamers) δ (ppm): 
5.05 (br s, 1 H), 4.94 (d, J = 6.7 Hz, 1 H, major rotamer), 4.79 (d, J = 6.6 
Hz, 1 H, minor rotamer), 4.10 (dd, J = 13.4, 4.1 Hz, 1 H, minor rotamer), 
3.96 (dd, J = 13.7, 4.1 Hz, 1 H, major rotamer), 3.75 (br s, 3 H), 3.74 (br s, 
3 H, major rotamer), 3.69 (br s, 3 H, minor rotamer), 3.44 (t, J = 13.1 Hz, 
1 H, major rotamer), 3.35 (t, J = 13.2 Hz, 1 H, minor rotamer), 2.97 (s, 3 
H), 2.73 (br s, 1 H, minor rotamer), 2.69 (br s, 1 H, major rotamer), 2.01 
(ddd, J = 14.8, 7.1, 2.1 Hz, 2 H), 1.85 – 1.68 (m, 1 H). 13C NMR (100.4 
MHz, CDCl3) (mixture of rotamers) δ (ppm): 171.4, 156.8 and 156.2, 74.4, 
53.1 and 52.5, 50.8 and 50.4, 38.5, 35.8 and 35.4, 31.8 and 31.6, 29.8 
and 29.6. MS (ESI) m/z (%): 318 ([M + Na]+, 100), 334 ([M + K]+, 38), 613 
([2M + Na]+, 48). HRMS (ESI/TOF) m/z: [M + H]+ Calcd. for C10H17NO7S: 
296.0799. Found: 296.0793. 
Dimethyl (–)-(2S,4S)-4-Azidopiperidine-1,2-dicarboxylate (10): 
Sodium azide (790 mg, 12.15 mmol) was added under nitrogen 
atmosphere to a solution of 9 (480 mg, 1.62 mmol) in anhydrous DMF 
(14.7 mL). The mixture was heated to 100 °C (external) for 3 h and then 
diluted with water (150 mL). The product was extracted with Et2O (3 × 
150 mL) and the combined organic extracts were dried over Na2SO4. 
After filtration and evaporation of the solvent, the crude residue was 
purified by flash chromatography (n-hexane-EtOAc, 3 : 1; Rf  0.24), and 
compound 10 (312 mg, 80%) was obtained as a pale yellow oil and as a 
94:6 mixture with the elimination product 11. [α]D
20 –6.2 (c 1.05, CHCl3). 
1H NMR (400 MHz, CDCl3) (1.4 : 1 mixture of rotamers) δ (ppm): 5.07 (br 
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d, J = 5.2 Hz, 1 H, major rotamer), 4.91 (br d, J = 5.2 Hz, 1 H, minor 
rotamer), 4.24 (br d, J = 13.1 Hz, 1 H, minor rotamer), 4.09 (br d, J = 13.8 
Hz, 1 H, major rotamer), 3.74 (br s, 3 H), 3.72 (br s, 3 H, major rotamer), 
3.69 (br s, 3 H, minor rotamer), 3.35 (tt, J = 12.0, 4.0 Hz, 1 H), 3.07 (t, J = 
13.4 Hz, 1 H, major rotamer), 2.97 (t, J = 12.8 Hz, 1 H, minor rotamer), 
2.47 (br t, J = 11.1 Hz, 1 H), 1.95 (br t, J = 14.8 Hz, 1 H), 1.73 – 1.56 (m, 
1 H), 1.46 (qd, J = 12.7, 4.3 Hz, 1 H). 13C NMR (100.4 MHz, CDCl3) 
(mixture of rotamers) δ (ppm): 171.1 and 171.0, 156.5 and 155.9, 55.2, 
53.9 and 53.7, 53.1 and 52.6, 40.2, 32.0 and 31.9, 30.4 and 30.3. MS 
(ESI) m/z (%): 265 ([M + Na]+, 87). 
(–)-(2S,4S)-4-Azidopiperidine-1,2-dicarboxylic acid 1-methyl ester 
(12): Aqueous 1 N NaOH (1.48 mL) was added to a solution of 10 (240 
mg, 0.99 mmol) in methanol (2.9 mL) and the resulting mixture was 
vigorously stirred for 2 h at room temperature. The methanol was 
removed under reduced pressure and the residue was diluted in water 
(23 mL). The resulting solution was acidified to pH 2 by the addition of 
aqueous 1 N HCl and the product was extracted with CH2Cl2 (3 × 23 mL). 
The aqueous layer was then further acidified to pH 1 and the product was 
extracted again with CH2Cl2 (3 × 23 mL). The combined organic extracts 
were dried over Na2SO4 and, after filtration and evaporation of the 
solvent, compound 12 (226 mg, quantitative) was obtained as a white 
solid. [α]D
20 –5.5 (c 0.96, CHCl3). 
1H NMR (400 MHz, CDCl3) (1.4 : 1 
mixture of rotamers) δ (ppm): 10.8 (br s, 1 H), 5.11 (br d, J = 5.5 Hz, 1 H, 
major rotamer), 4.96 (br d, J = 5.1 Hz, 1 H, minor rotamer), 4.24 (br d, J = 
13.0 Hz, 1 H, minor rotamer), 4.11 (br d, J = 13.8 Hz, 1 H, major rotamer), 
3.74 (br s, 3 H, major rotamer), 3.71 (br s, 3 H, minor rotamer), 3.42 (tt, J 
= 11.9, 3.8 Hz, 1 H), 3.17 – 2.95 (m, 1 H), 2.51 (br t, J = 14.2 Hz, 1 H), 
1.98 (br t, J = 14.9 Hz, 1 H), 1.69 (td, J = 12.8, 6.3 Hz, 1 H), 1.48 (qd, J = 
12.6, 4.6 Hz, 1 H). 13C NMR (100.4 MHz, CDCl3) (mixture of rotamers) δ 
(ppm): 175.9 and 175.8, 156.9 and 156.1, 55.1, 53.7 and 53.6, 53.4 and 
53.3, 40.3, 31.8 and 31.7, 30.3 and 30.2. MS (ESI) m/z (%) (negative 
mode): 227 ([M - 1]-, 81), 455 ([2M - 1]-, 100). 
(–)-(2S,4S)-4-(9H-Fluorenylmethoxycarbonylamino)-piperidine-1,2-
dicarboxylic acid 1-methyl ester (14): To a solution of 12 (217 mg, 0.95 
mmol) in anhydrous MeOH (18.1 mL), 10% Pd/C (32 mg, 0.03 mmol) 
was added under a nitrogen atmosphere. The resulting suspension was 
first flushed with hydrogen under vigorous stirring and then maintained 
under a hydrogen atmosphere (balloon) at room temperature. After 24 h, 
the mixture was filtered over a Celite pad, and the residual solution was 
evaporated under reduced pressure. The amino acid 13 (205 mg, 
quantitative) was obtained as a white solid and immediately used in the 
next step without further purifications. 1H NMR (400 MHz, CD3OD) (1.5 : 
1 mixture of rotamers) δ (ppm): 4.76 (br d, J = 5.4 Hz, 1 H, minor 
rotamer), 4.68 (br d, J = 5.0 Hz, 1 H, major rotamer), 4.15 – 4.02 (m, 1 H), 
3.70 (br s, 3 H, major rotamer), 3.67 (br s, 3 H, minor rotamer), 3.29 – 
3.14 (m, 1 H), 3.09 (tt, J = 12.1, 3.6 Hz, 1 H), 2.67 – 2.52 (m, 1 H), 2.02 – 
1.85 (m, 1 H), 1.65 – 1.51 (m, 1 H), 1.48 – 1.34 (m, 1 H). MS (ESI) m/z 
(%) (negative mode): 201 ([M - 1]-, 100). A 10% aqueous solution of 
Na2CO3 (2.92 mL) was added to a suspension of amino acid 13 (192 mg, 
0.95 mmol) in THF (2.3 mL) and the resulting mixture was cooled to 0 °C. 
After the addition of a solution of Fmoc–OSu (320 mg, 0.95 mmol) in THF 
(7.3 mL), the ice bath was removed and the mixture was vigorously 
stirred at room temperature for 19 h. The solvent was evaporated under 
reduced pressure and the residue was taken up in EtOAc (20 mL). The 
organic solution was washed once with water (15 mL) and once with  
satd NH4Cl (10 mL). The aqueous phases were then reunited and 
extracted with EtOAc (5 × 20 mL). The aqueous layer was then acidified 
down to pH 2 by the addition of aqueous 0.5 N HCl and extracted again 
with EtOAc (10 × 20 mL). The combined organic extracts were dried over 
Na2SO4. After filtration and evaporation of the solvent, the crude residue 
was purified by flash chromatography, eluting first with DCM-MeOH, 20 : 
1 and then with DCM-MeOH, 7.5 : 1 (Rf 0.27). Pure compound 14 (319 
mg, 79%) was obtained as a clear syrup. [α]D
22 –8.6 (c 1.02, CHCl3). 
1H 
NMR (400 MHz, CD3OD) (1.3 : 1 mixture of rotamers) δ (ppm): 7.77 (d, J 
= 7.5 Hz, 2 H), 7.61 (d, J = 7.1 Hz, 2 H), 7.37 (t, J = 7.4 Hz, 2 H), 7.28 (t, 
J = 7.3 Hz, 2 H), 4.78 (br s, 1 H, minor rotamer), 4.72 (br s, 1 H, major 
rotamer), 4.32 (d, J = 6.5 Hz, 2 H), 4.18 (br d, J = 6.4 Hz, 1 H), 4.02 (br t, 
J = 14.0 Hz, 1 H), 3.67 (s, 3 H, minor rotamer), 3.65 (s, 3 H, major 
rotamer), 3.48 (br t, J = 11.2 Hz), 3.23 – 3.06 (m, 1 H), 2.53 – 2.39 (m, 1 
H), 1.85 (br t, J = 12.8 Hz, 1 H), 1.50 (br s, 1 H), 1.39 – 1.23 (m, 1 H). 13C 
NMR (100.4 MHz, CD3OD) (mixture of rotamers) δ (ppm): 176.8 and 
175.3, 158.7 and 158.5, 158.0, 145.3 (2 C), 142.6 (2 C), 128.7 (2 C), 
128.1 (2 C), 126.1 (2 C), 120.9 (2 C), 67.7, 56.8 and 56.6, 53.4 and 53.3, 
47.2, 41.9, 34.4 and 34.2, 32.5 and 32.4, 26.2. HRMS (ESI/TOF) m/z: [M 
+ Na]+ Calcd. for C23H24N2O6Na: 447.1527. Found: 447.1511. 
Dimethyl (–)-(2S,4S)-4-Hydroxypiperidine-1,2-dicarboxylate (16): A 
solution of 7 (232 mg, 1.07 mmol) and Ph3P (422 mg, 1.61 mmol) in 
anhydrous THF (8 mL) was added to a solution of diisopropyl 
azodicarboxylate (DIAD) (317 µL, 1.61 mmol) and acetic acid (92 µL, 
1.61 mmol) in anhydrous THF (8 mL), cooled to 0 °C and under nitrogen 
atmosphere. After 1 h, a second portion of PPh3 (84 mg, 0.32 mmol) and 
DIAD (31 µL, 0.16 mmol) was added and the mixture was stirred at 0 °C 
for an additional 3 h. The solvent was then removed under reduced 
pressure and the residue was taken up into n-hexane-Et2O, 1 : 1 (20 mL). 
After filtration on a Celite pad and evaporation of the solvent, the crude 
residue was purified by flash chromatography (n-hexane-EtOAc, 1 : 2; Rf 
0.35) to afford acetate 15 (in a 1 : 1.6 ratio with a residual impurity of 
reduced DIAD) as a colourless oil (193 mg). 1H NMR (400 MHz, CDCl3) 
(1.7 : 1 mixture of rotamers) δ (ppm): 5.11 – 5.00 (m, 1 H, minor rotamer), 
5.01 – 4.86 (m, 1 H, major rotamer), 4.72 (tt, J = 11.5, 4.3 Hz, 1 H), 4.21 
(br d, J = 12.9 Hz, 1 H, minor rotamer), 4.06 (br d, J = 12.2 Hz, 1 H, 
major rotamer), 3.75 (s, 3 H), 3.73 (br s, 3 H, major rotamer), 3.71 (br s, 
3 H, minor rotamer), 3.22 – 3.00 (m, 1 H), 2.47 (br d, J = 12.1 Hz, 1 H), 
2.06 – 1.95 (m, 4 H), 1.74 (td, J = 12.4, 6.3 Hz, 1 H), 1.54 – 1.40 (m, 1 H). 
A solution of 15 in anhydrous MeOH was cooled to 0 °C, under nitrogen 
atmosphere, and MeONa (84 mg, 1.55 mmol) was added. After 6 h, 
glacial acetic acid (825 µL) was added and the solvent was evaporated. 
The residue was diluted with water (40 mL), the product was extracted 
with EtOAc (4 × 50 mL) and the combined organic extracts were dried 
over Na2SO4. After filtration and evaporation of the solvent, the crude 
residue was purified by flash chromatography (n-hexane-EtOAc, 1 : 2; Rf 
0.25) to afford 16 (76 mg, 33% over two steps) as a colourless oil. [α]D
21 
–25.3 (c 1.0, CHCl3). 
1H NMR (400 MHz, CDCl3) (1.4 : 1 mixture of 
rotamers) δ (ppm): 5.03 (br d, J = 4.7 Hz, 1 H, major rotamer), 4.88 (br d, 
J = 3.9 Hz, 1 H, minor rotamer), 4.18 (br d, J = 13.1 Hz, 1 H, minor 
rotamer), 4.05 (br d, J = 13.2 Hz, 1 H, major rotamer), 3.72 (s, 3 H), 3.71 
(br s, 3 H, major rotamer), 3.68 (br s, 3 H, minor rotamer), 3.64 (tt, J = 
11.2, 4.2 Hz, 1 H), 3.03 (dt, J = 27.3, 13.0 Hz, 1 H), 2.51 – 2.37 (m, 1 H), 
2.21 – 1.96 (m, 1 H), 1.96 – 1.82 (m, 1 H), 1.60 (ddd, J = 12.8, 11.7, 6.3 
Hz, 1 H), 1.40 (qd, J = 12.7, 4.4 Hz, 1 H). Spectroscopical data are 
identical to those reported in literature for its enantiomer.[4b] 
Dimethyl (+)-(2S,4R)-4-Azidopiperidine-1,2-dicarboxylate (18): 
Prepared as reported for (–)-9, starting from 16 (76 mg, 0.35 mmol) and 
obtaining the intermediate O-mesylate 17 (99 mg, quantitative) after 
purification by flash chromatography (n-hexane-EtOAc, 1 : 1; Rf 0.28) as 
a colourless oil. 1H NMR (400 MHz, CDCl3) (1.4 : 1 mixture of rotamers) 
δ (ppm): 5.12 (br s, 1 H, major rotamer), 4.97 (br s, 1 H, minor rotamer), 
4.67 (tt, J = 11.5, 4.5 Hz, 1 H), 4.27 (br d, J = 13.7 Hz, 1 H, minor 
rotamer), 4.12 (br d, J = 13.5 Hz, 1 H, major rotamer), 3.78 (s, 3 H), 3.74 
(br s, 3 H, major rotamer), 3.72 (br s, 3 H, minor rotamer), 3.18 – 3.05 (m, 
1 H), 3.04 (s, 3 H), 2.66 (br s, 1 H, minor rotamer), 2.63 (br s, 1 H, major 
rotamer), 2.16 (br s, 1 H), 1.90 (ddd, J = 12.8, 11.9, 6.3 Hz, 1 H), 1.72 
(ddd, J = 24.4, 12.6, 5.0 Hz, 1 H). The O-mesylate 17 (99 mg, 0.35 
mmol) was treated with NaN3 (170 mg, 2.62 mmol) as reported for 
compound (+)-10 and pure (+)-18 was obtained as a pale yellow oil (65 
mg, 81%) after purification by flash chromatography (n-hexane-EtOAc, 
1 : 1; Rf 0.42). [α]D
20 +39.1 (c 0.52, CHCl3). 
1H NMR (400 MHz, CDCl3) 
(1.4 : 1 mixture of rotamers) δ (ppm): 4.87 (br s, 1 H, major rotamer), 
4.72 (br s, 1 H, minor rotamer), 4.02 (br d, J = 3.6 Hz, 1 H, minor 
rotamer), 3.98 (quint, J = 3.1 Hz, 1 H), 3.87 (br d, J = 11.9 Hz, 1 H, major 
rotamer), 3.78 (s, 3 H), 3.73 (br s, 3 H, major rotamer), 3.70 (br s, 3 H, 
minor rotamer), 3.39 – 3.17 (m, 1 H), 2.55 (br s, 1 H, minor rotamer), 
2.52 (br s, 1 H, major rotamer), 1.98 (dd, J = 6.7, 2.9 Hz, 1 H, major 
rotamer), 1.98 (dd, J = 6.7, 2.9 Hz, 1 H, minor rotamer), 1.85 – 1.62 (m, 2 
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H). 13C NMR (100.4 MHz, CDCl3) (mixture of rotamers) δ (ppm): 171.4, 
156.8, 54.4, 53.0, 52.4, 51.1 and 50.8, 36.2 and 36.0, 30.4 and 30.3, 
28.7 and 28.5. MS (ESI) m/z (%): 243 ([M + H]+, 19), 265 ([M + Na]+, 
100), 507 ([2M + Na]+, 17). HRMS (ESI/TOF) m/z: [M + Na]+ Calcd. for 
C9H14N4O4Na: 265.0907. Found: 265.0916. 
(2S,4R)-4-Hydroxypiperidine-2-carboxylic acid Hydrochloride (1·HCl) 
(20): A vigorously stirred dispersion of 7 (83 mg, 0.41 mmol) in a 2 N HCl 
aqueous solution (23.4 mL) was refluxed for 21 h. The mixture was then 
cooled to room temperature, washed with Et2O (2 x 40 mL), and the 
aqueous layer concentrated under vacuum. The aminoacid 20 was 
obtained as a white solid (75 mg, quantitative) and immediately used in 
the next step without further purification. Analytical and spectroscopic 
data are identical to those reported in literature.[4c]  
(2S,4R)-1-(tert-Butoxycarbonyl)-4-hydroxypiperidine-2-carboxylic 
acid (21): To a solution of compound 20 (75 mg, 0.41 mmol) in 
anhydrous methanol (9.1 mL), triethylamine (172 µL, 1.23 mmol) and 
Boc2O (179 mg, 0.82 mmol) were added, under a nitrogen atmosphere, 
and the resulting reaction mixture was heated under reflux. After 21 h, 
the solvent was evaporated under reduced pressure and the residue was 
dissolved in H2O (5 mL). NaH2PO4·2H2O (7 mg) was added and the 
resulting solution was cooled to 0 °C, acidified down to pH 3 by addition 
of aqueous 0.5 N HCl and then stirred for 30 min at 0 °C. The product 
was then extracted with EtOAc (4 x 7 mL) and the combined organic 
extracts were dried over Na2SO4. After filtration and evaporation of the 
solvent, the crude N-Boc protected compound 21 (101 mg, quantitative) 
was obtained and used in the next step without further purification. The 
spectroscopical data are identical to those reported in the literature.[30] 
2-Benzyl 1-tert-Butyl (–)-(2S,4R)-4-Hydroxypiperidine-1,2-
dicarboxylate (22): To a solution of the N-Boc protected compound 21 
(250 mg, 1.02 mmol) and K2CO3 (153 mg, 1.11 mmol) in anhydrous DMF 
(23 mL), cooled at 0 °C and under a nitrogen atmosphere, benzyl 
bromide (122 µL, 1.02 mmol) was added. The ice bath was removed and 
the resulting mixture was stirred at room temperature for 24 h. Water 
(115 mL) was added, the product was extracted with EtOAc (58 mL) and 
the organic extract dried over Na2SO4. After filtration and evaporation of 
the solvent, the crude product was purified by flash chromatography (n-
hexane-EtOAc, 3 : 2; Rf 0.38) to afford pure 22 (305 mg, 89%) as a 
colourless oil. [α]D
20 –38.0 (c 1.04, CHCl3). 
1H NMR (400 MHz, CDCl3) 
(1.1 : 1 mixture of rotamers) δ (ppm): 7.39 – 7.27 (m, 5 H), 5.27 – 5.01 
(m, 2 H), 4.87 (br s, 1 H, major rotamer), 4.67 (br s, 1 H, minor rotamer), 
4.11 (br s, 1 H), 3.90 (br d, J = 11.3 Hz, 1 H, minor rotamer), 3.77 (br d, J 
= 10.1 Hz, 1 H, major rotamer), 3.47 – 3.24 (m, 1 H), 2.43 (br d, J = 13.2 
Hz, 1 H), 1.90 (ddd, J = 14.4, 6.8, 2.3 Hz, 1 H), 1.80 – 1.49 (m, 3 H). 13C 
NMR (100.4 MHz, CDCl3) (mixture of rotamers) δ (ppm): 172.7 and 172.5, 
155.8 and 155.3, 135.7, 128.5 (2 C), 128.2 (3 C), 80.1, 66.8, 63.3, 51.6 
and 50.4, 36.1 and 35.0, 33.4, 31.1, 28.3 (3 C). MS (ESI) m/z (%): 358 
([M + Na]+, 99), 693 ([2M + Na]+, 100). HRMS (ESI/TOF) m/z: [M + Na]+ 
Calcd. for C18H25NO5Na: 358.1625. Found: 358.1623. 
2-Benzyl 1-tert-Butyl (–)-(2S,4R)-4-Methanesulfonyloxypiperidine-
1,2-dicarboxylate (23): Prepared as reported for (–)-9, starting from 22 
(405 mg, 1.21 mmol) and obtaining pure O-mesylate 23 (419 mg, 84%) 
as a colourless oil, after purification of the crude by flash chromatography 
(n-hexane-EtOAc, 2 : 1; Rf 0.31). [α]D
19 –17.2 (c 1.0, CHCl3). 
1H NMR 
(400 MHz, CDCl3) (1.2 : 1 mixture of rotamers) δ (ppm): 7.42 – 7.29 (m, 5 
H), 5.29 – 5.10 (m, 2 H), 5.05 (br s, 1 H), 4.95 (br d, J = 6.8 Hz, 1 H, 
major rotamer), 4.74 (br d, J = 5.7 Hz, 1 H, minor rotamer), 4.03 (br d, J = 
9.7 Hz, 1 H, minor rotamer), 3.91 (br d, J = 9.6 Hz, 1 H, major rotamer), 
3.41 (br t, J = 13.2 Hz, 1 H, minor rotamer), 3.30 (br t, J = 11.9 Hz, 1 H, 
major rotamer), 2.81 (br s, 3 H, minor rotamer), 2.77 (br s, 3 H, major 
rotamer), 2.73 (br s, 1 H, minor rotamer), 2.69 (br s, 1 H, major rotamer), 
2.11 – 1.96 (m, 2 H), 1.76 (br t, J = 11.8 Hz, 1 H), 1.45 (br s, 9 H, major 
rotamer), 1.39 (br s, 9 H, minor rotamer). 13C NMR (100.4 MHz, CDCl3) 
(mixture of rotamers) δ (ppm): 171.2 and 171.0, 155.6 and 155.1, 135.5, 
128.6 (2 C), 128.3 (3 C), 80.6, 74.4 and 74.2, 67.2, 51.3 and 50.1, 38.3, 
36.1 and 35.1, 31.6 and 31.4, 29.9 and 29.6, 28.3 (3 C). MS (ESI) m/z 
(%): 436 ([M + Na]+, 39), 849 ([2M + Na]+, 100). Elem. Anal. Calcd for 
C19H27NO7S: C, 55.19; H 6.58; N 3.39. Found: C, 54.96; H, 6.81; N, 3.18. 
2-Benzyl 1-(tert-Butyl) (2S,4S)-4-Bromopiperidine-1,2-dicarboxylate 
(24): To a solution of O-mesylate 23 (419 mg, 1.02 mmol) in anhydrous 
DMF (9.3 mL), LiBr (133 mg, 1.53 mmol) was added. The mixture was 
stirred for 2 days at 70 °C, then taken up into EtOAc (90 mL), washed 
with water (90 mL) and dried over Na2SO4. After filtration and 
evaporation of the solvent, the crude product was purified by flash 
chromatography (n-hexane-EtOAc, 7 : 1; Rf  0.45) and the pale yellow oil 
so obtained contained 24 (194 mg, 48%) as a 88:12 mixture with the 
elimination product 25. [α]D
24 –38.4 (c 1.0, CHCl3). 
1H NMR (400 MHz, 
CDCl3) (1.25 : 1 mixture of rotamers) δ (ppm): 7.40 – 7.27 (m, 5 H), 5.18 
(br s, 2 H), 5.00 (br d, J = 3.5 Hz, 1 H, major rotamer), 4.77 (br d, J = 4.2 
Hz, 1 H, minor rotamer), 4.13 – 3.99 (m, 1 H, minor rotamer), 3.99 – 3.82 
(m, 2 H, major rotamer), 3.01 (br t, J = 12.3 Hz, 1 H, major rotamer), 2.92 
(br t, J = 13.2 Hz, 1 H, minor rotamer), 2.78 (br t, J = 15.2 Hz, 1 H), 2.29 
– 2.05 (m, 2 H), 1.89 (qd, J = 12.8, 4.9 Hz, 1 H), 1.44 (br s, 9 H, major 
rotamer), 1.35 (br s, 9 H, minor rotamer). 13C NMR (100.4 MHz, CDCl3) 
(mixture of rotamers) δ (ppm): 170.7 and 170.6, 155.3 and 154.9, 135.3, 
128.6 (3 C), 128.2, 128.0, 80.7, 67.1, 56.1 and 55.2, 44.2 and 44.1, 42.6 
and 41.9, 37.4, 36.4 and 36.3, 28.2 (3 C). MS (ESI) m/z (%): 420 ([M + 
Na]+, 73) and 422 ([M + Na]+, 66). 
(2S,4R)-4-Azidopiperidine-1,2-dicarboxylic acid 2-benzyl ester 1-tert-
butyl ester (26): Sodium azide (238 mg, 3.66 mmol) was added under 
nitrogen atmosphere to a solution of the bromide derivative 24 (194 mg, 
0.49 mmol) in anhydrous DMF (4.9 mL). The mixture was heated to 
70 °C (external) for 22 h and then diluted with water (50 mL). The product 
was extracted with Et2O (3 × 50 mL) and the combined organic extracts 
were dried over Na2SO4. After filtration and evaporation of the solvent, 
the crude residue was then purified by flash chromatography (n-hexane-
EtOAc, 7 : 1; Rf  0.27) and the pale yellow oil 26 (174 mg, 98%) was 
obtained as an 84:16 mixture with the elimination and consecutive 
isomerization product 27. 1H NMR (400 MHz, CDCl3) (1.2 : 1 mixture of 
rotamers) δ (ppm): 7.44 – 7.27 (m, 5 H), 5.32 – 5.16 (m, 2 H), 4.86 (br s, 
1 H, major rotamer), 4.67 (br s, 1 H, minor rotamer), 3.99 – 3.87 (m, 1 H), 
3.36 – 3.10 (m, 1 H), 2.50 (br d, J = 12.9 Hz, 1 H), 1.93 (ddd, J = 14.4, 
6.8, 3.0 Hz, 1 H), 1.85 – 1.61 (m, 2 H), 1.45 (br s, 9 H, major rotamer), 
1.37 (br s, 9 H, minor rotamer). MS (ESI) m/z (%): 383 ([M + Na]+, 100). 
HRMS (ESI/TOF) m/z: [M + H]+ Calcd. for C18H24N4O4: 361.1870. Found: 
361.1871. 
(2S,4R)-4-Aminopiperidine-1,2-dicarboxylic acid 1-tert-butyl ester 
(28): To a solution of 26 (174 mg, 0.48 mmol) in anhydrous MeOH (12.6 
mL), 10% Pd/C (16 mg, 15 µmol) was added under a nitrogen 
atmosphere. The resulting suspension was first flushed with hydrogen 
under vigorous stirring and then maintained under a hydrogen 
atmosphere (balloon) at room temperature. After 4.5 h, the mixture was 
filtered over a Celite pad, and the residual solution was evaporated under 
reduced pressure. The amino acid 28 (118 mg, quantitative) was 
obtained as a white solid and immediately used in the next step without 
further purification. 1H NMR (400 MHz, CD3OD) δ (ppm): 4.48 (br s, 1 H), 
3.90 – 3.79 (m, 1 H), 3.41 – 3.36 (m, 1 H), 3.33 – 3.31 (m, 1 H), 2.21 – 
2.09 (m, 1 H), 2.08 – 1.96 (m, 1 H), 1.94 – 1.83 (m, 1 H), 1.83 – 1.71 (m, 
1 H), 1.46 (s, 9 H). MS (ESI) m/z (%): 267 ([M + Na]+, 100), 511 ([2M + 
Na]+, 65). 
(2S,4R)-4-(9H-Fluoren-9-ylmethoxycarbonylamino)-piperidine-1,2-
dicarboxylic acid 1-tert-butyl ester (29): A 10% aqueous solution of 
Na2CO3 (1.47 mL) was added to a suspension of amino acid 28 (118 mg, 
0.48 mmol) in THF (1.5 mL) and the resulting mixture was cooled to 0 °C. 
After the addition of a solution of Fmoc–OSu (162 mg, 0.48 mmol) in THF 
(4.5 mL), the ice bath was removed and the mixture was vigorously 
stirred at room temperature for 19 h. The solvent was evaporated under 
reduced pressure and the residue was taken up in EtOAc (24 mL). The 
organic solution was washed once with water (24 mL) and once with satd 
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NH4Cl (24 mL). The aqueous phases were then reunited and extracted 
with EtOAc (3 × 24 mL). The acqueos layer was then acidified to pH 3 by 
the addition of aqueous 1 N HCl and the product was extracted with 
EtOAc (8 × 24 mL). Finally, the aqueous layer was then further acidified 
to pH 2 and the product was extracted again with EtOAc (24 mL). The 
combined organic extracts were dried over Na2SO4. After filtration and 
evaporation of the solvent, the crude residue was chromatographed 
(MeOH-DCM, 1 : 20; Rf 0.22) to provide 29 (174 mg, 78%) as a 
colourless oil. A small sample of compound 29 was further purified by 
semi-preparative HPLC (water–acetonitrile eluent buffered with 0.1% 
TFA, acetonitrile from 50 to 90%; Rt = 10.48 min) for characterization. 
[α]D
20 –6.0 (c 1.0, CH3OH). 
1H NMR (400 MHz, CD3OD) δ (ppm): 7.79 (d, 
J = 7.5 Hz, 2 H), 7.69 – 7.59 (m, 2 H), 7.39 (t, J = 7.4 Hz, 2 H), 7.35 – 
7.28 (m, 2 H), 4.52 (br s, 1 H), 4.39 – 4.16 (m, 3 H), 3.75 (br s, 2 H), 3.45 
– 3.33 (m, 1 H), 2.59 – 2.49 (m, 1 H), 1.96 – 1.88 (m, 1 H), 1.86 – 1.78 
(m, 1 H), 1.77 – 1.69 (m, 1 H), 1.46 (s, 9 H). 13C NMR (100.4 MHz, 
CD3OD) (mixture of rotamers) δ (ppm): 176.2 and 175.4, 158.1 and 157.4, 
145.3 (2 C), 142.5 (2 C), 128.7 (2 C), 128.1 (2 C), 126.2 (2 C), 120.9 (2 
C), 81.6 and 81.3, 67.8, 56.3 and 55.1, 45.5, 43.2 and 42.2, 37.8, 31.3, 
29.7, 28.6 (3 C). MS (ESI) m/z (%): 489 ([M + Na]+, 100). HRMS 
(ESI/TOF) m/z: [M + H]+ Calcd. for C26H30N2O6: 467.2175. Found: 
467.2177.  
(–)-(2S,4S)-4-(9-Fluorenylmethoxycarbonylamino)-1-
(methoxycarbonyl)piperidine-2-Arg(Mtr)-Gly-OBn (30): DEPBT (359 
mg, 1.20 mmol) and DIPEA (209 µL, 1.20 mmol) were added under a 
nitrogen atmosphere to a solution of 14 (256 mg, 0.60 mmol) in 
anhydrous THF (5.5 mL), cooled to 0 °C, and the resulting mixture was 
allowed to warm to room temperature. After 15 min, the reaction mixture 
was cooled again to 0 °C, and a solution of H-Arg(Mtr)-Gly-OBn (428 mg, 
0.78 mmol) in anhydrous THF (5.5 mL) was added. The ice bath was 
removed and the mixture was stirred at 35 °C (external) for 24 h and then 
stirred at 25 °C for 3 days. The mixture was then diluted with EtOAc (225 
mL), washed with satd NH4Cl (2 × 60 mL), satd NaHCO3 (2 × 60 mL), 
and finally with H2O (2 × 60 mL). The organic extract was dried over 
Na2SO4, filtered, and evaporated under reduced pressure. The crude 
residue was purified by flash chromatography (MeOH-DCM, 1 : 20; Rf  
0.41) and pure 30 (484 mg, 86 %) was obtained as a white gummy solid. 
m.p. = 147.4 – 151.3 °C. [α]D
24 –10.4 (c 1.04, CHCl3). 
1H NMR (400 MHz, 
CDCl3) δ (ppm): 7.73 (d, J = 7.4 Hz, 2 H), 7.66 (br s, 1 H), 7.51 (d, J = 7.3 
Hz, 2 H), 7.37 (t, J = 7.5 Hz, 2 H), 7.32 – 7.16 (m, 7 H), 6.48 (s, 1 H), 
6.31 (br s, 2 H), 5.13 – 4.95 (m, 3 H), 4.81 (br s, 1 H), 4.61 (br s, 1 H), 
4.28 (br d, J = 5.1 Hz, 2 H), 4.15 – 3.94 (m, 3 H), 3.79 (s, 3 H), 3.68 (s, 3 
H), 3.55 (br s, 1 H), 3.35 – 3.12 (m, 2 H), 2.65 (s, 3 H), 2.58 (s, 4 H), 2.08 
(s, 3 H), 2.03 – 1.92 (m, 1 H), 1.92 – 1.48 (m, 7 H). 13C NMR (100.4 MHz, 
CDCl3) δ (ppm): 172.2, 169.8, 158.3, 156.5, 156.4, 155.7, 143.7, 141.2, 
138.5, 136.4, 135.3, 133.5, 128.5, 128.2 (2 C), 128.2, 128.1 (2 C), 127.7 
(2 C), 127.0 (2 C), 124.9, 124.7, 119.9 (2 C), 111.6, 67.0, 66.8, 66.7, 
55.4, 54.9, 53.2, 47.1, 45.7, 41.3, 40.4, 33.4, 31.2, 29.7, 29.6, 25.5, 24.1, 
18.3, 11.9. MS (ESI) m/z (%): 962 ([M + Na]+, 100). 
(2S,4S)-4-[L-Phe-Z-Asp(OtBu)]-1-(methoxycarbonyl)-4-APA-2-
Arg(Mtr)-Gly-OBn (32): Compound 30 (244 mg, 0.26 mmol) was 
dissolved in a 1 : 1 CH2Cl2/diethylamine mixture (4.2 mL) under a 
nitrogen atmosphere. The resulting solution was stirred at room 
temperature for 4 h, meanwhile an additional 1 : 1 CH2Cl2/diethylamine 
mixture (1.5 mL) was added. The solution was concentrated under 
reduced pressure, the residue was taken up in CH2Cl2 (3.5 mL), filtered 
over a Celite pad and then concentrated again. The crude 31 was 
obtained as a pale yellow solid. 1H NMR (400 MHz, CDCl3) (2.1 : 1 
mixture of rotamers) δ (ppm): 7.34 – 7.26 (m, 5 H), 6.50 (s, 1 H), 6.41 (br 
s, 1 H), 5.16 – 5.04 (m, 2 H), 4.97 (br s, 1 H, major rotamer), 4.86 (br s, 1 
H, major rotamer), 4.58 (br s, 1 H), 4.16 – 4.03 (m, 3 H), 3.80 (s, 3 H), 
3.67 (s, 3 H), 3.41 – 3.08 (m, 3 H), 3.01 (br s, 1 H), 2.65 (s, 3 H), 2.58 (s, 
3 H), 2.58 (s, 3 H), 2.00 – 1.79 (m, 2 H), 1.70 (br s, 1 H), 1.56 (br s, 3 H), 
1.30 – 1.22 (m, 3 H), 1.20 – 1.02 (m, 1 H). MS (ESI) m/z (%): 313 ([M – 
CH2Ph]
2+, 100), 718 ([M + 1]+, 97). DEPBT (200 mg, 0.67 mmol) and 
DIPEA (86 µL, 0.67 mmol) were added under nitrogen atmosphere to a 
solution of Z-Asp(OtBu)-L-Phe-OH (207 mg, 0.38 mmol) in anhydrous 
THF (4.5 mL), cooled at 0 °C, and the resulting mixture was allowed to 
warm to room temperature. After 15 min, this solution was slowly added 
to a solution of compound 31 in anhydrous THF (1.5 mL), precooled to 
0 °C. The ice bath was removed and the resulting mixture was stirred at 
35 °C. After 24 h, a second portion of Z-Asp(OtBu)-L-Phe-OH (61 mg, 
0.13 mmol), DEPBT (77 mg, 0.26 mmol) and DIPEA (45 µL, 0.26 mmol) 
was added and the mixture was stirred at 35 °C for an additional 3 days. 
The mixture was then diluted with EtOAc (57 mL) and washed with satd 
NH4Cl (2 × 16 mL), satd NaHCO3 (2 × 16 mL) and finally H2O (2 × 16 
mL). The organic layer was dried over Na2SO4, filtered and evaporated 
under reduced pressure. The crude residue was purified by flash 
chromatography (MeOH/CH2Cl2 1:15, Rf 0.30) and pure 32 (284 mg, 
98%) was obtained as a white solid. m.p. 103.4 – 109.1 °C. [α]D
26 –14.5 
(c 0.99, CHCl3). 
1H NMR (400 MHz, CDCl3) δ (ppm): 7.73 (br m, 1 H), 
7.45 – 7.05 (m, 15 H), 6.89 (br s, 1 H), 6.50 (s, 1 H), 6.37 (br s, 2 H), 5.88 
(br s, 1 H), 5.10 (br s, 2 H), 5.09 – 4.91 (m, 2 H), 4.66 (br s, 1 H), 4.51 (br 
s, 1 H), 4.46 – 4.28 (m, 1 H), 4.16 – 3.91 (m, 4 H), 3.83 – 3.74 (m, 1 H), 
3.79 (s, 3 H), 3.66 (s, 3 H), 3.43 – 3.09 (m, 3 H), 3.00 (br s, 2 H), 2.72 – 
2.65 (m, 1 H), 2.67 (br s, 3 H), 2.60 (s, 3 H), 2.47 – 2.38 (m, 1 H), 2.10 (s, 
3 H), 1.95 (br s, 1 H), 1.79 – 1.47 (m, 4 H), 1.38 (s, 9 H) 1.43 – 1.17 (m, 3 
H). 13C NMR (100.4 MHz, CDCl3) (mixture of rotamers) δ (ppm): 172.1, 
170.79 and 170.76, 170.64 and 170.57, 170.3, 169.8, 158.3, 157.1, 
156.5, 156.1, 138.5, 136.4, 136.2, 135.8, 135.3, 135.2, 133.6, 129.2, 
128.7, 128.53, 128.50, 128.4, 128.3, 128.2, 128.0, 127.0, 124.7, 111.7, 
82.0, 67.3, 66.9, 55.4, 54.8, 54.4, 53.2, 52.6, 51.7, 44.3, 41.4 and 41.2, 
40.3, 37.2, 32.4, 30.5, 29.7, 29.6, 29.3, 28.0 (3 C), 25.5, 24.1, 18.3, 11.9. 
MS/MS (ESI) [M + Na]+ m/z (%): 1192 ([M + Na]+, 4), 1136 (100). 
(–)-Cyclo{Arg-Gly-Asp-L-Phe[1-(methoxycarbonyl)-4-APA]}·TFA (34): 
To a solution of 32 (284 mg, 0.25 mmol) in ethanol (14.3 mL), 10% Pd/C 
(157 mg, 0.15 mmol) was added under a nitrogen atmosphere. The 
resulting suspension was first flushed with hydrogen under vigorous 
stirring and then maintained under a hydrogen atmosphere (balloon) at 
room temperature. After 18 h, the mixture was filtered over a Celite pad, 
filtered again through a syringe filter (Nylon, 0.45 µm pores) and the 
residual solution was evaporated under reduced pressure. Compound 33 
(213 mg, 90%) was obtained as a white solid and used in the next step 
without further purifications. MS (ESI) m/z (%): 968 ([M + Na]+, 100). The 
crude 33 (213 mg, 0.23 mmol) was suspended in THF (66 mL) under a 
nitrogen atmosphere. The suspension was cooled to 0 °C, and DEPBT 
(202 mg, 0.68 mmol) and DIPEA (117 µL, 0.68 mmol) were added. The 
resulting mixture was stirred at 35 °C for 5 days and the diluted with 
EtOAc (22 mL), washed with satd NH4Cl (2 × 15 mL), satd NaHCO3 (2 × 
15 mL), H2O (2 × 15 mL) and finally dried over Na2SO4. After filtration 
and evaporation of the solvent, the residue was purified by flash 
chromatography (MeOH/CH2Cl2 1:20, Rf 0.10). Cromatography column 
was then washed with MeOH. The MeOH solution was concentrated, 
taken up in CHCl3, washed with water (3 x 15 mL) and finally 
concentrated again. The cyclopeptide (116 mg, 59%) was obtained ad a 
white solid. MS (ESI) m/z (%): 950 ([M + Na]+, 100). The crude cyclic 
tetrapeptide was dissolved in a 95:2,5:2,5 trifluoroacetic 
acid/triisopropylsilane/H2O mixture (6,5 mL) and the resulting solution 
was stirred at room temperature for 24 h. The mixture was concentrated 
under reduced pressure, and the residue was taken up in H2O (6 mL) 
and washed with Et2O (4 × 6 mL). The aqueous layer was then 
concentrated under reduced pressure to afford the deprotected cyclic 
tetrapeptide as a trifluoroacetate salt. This crude was purified by semi-
preparative HPLC (Rt = 10.33 min) and pure 34 (10.4 mg, 11%) was 
obtained as a white spongy solid by lyophilisation of the HPLC sample. 
The purity of the final compound was checked by analytical HPLC. [α]D
26 
–36.0 (c 0.27, CH3OH). 
1H NMR (500 MHz, D2O/H2O 1:9) (1.8 : 1 mixture 
of rotamers) δ (ppm): 8.61 (s, 1 H, NH Asp), 8.41-8.34 (m, 1 H, NH Arg), 
8.13 (d, J = 6.0 Hz, 1 H, NH Phe), 8.02 – 7.97 (m, 1 H, NH Gly), 7.80 
(d, J = 5.5 Hz, 1 H, NH 4-APA), 7.33 – 7.07 (m, 5 H, CHarom Phe), 6.57 
(br s, 5 H, NHε Arg), 4.85 (d, J = 13.9 Hz, 1 H, 2-H), 4.48 – 4.40 (m, 1 H, 
Hα Arg), 4.37 – 4.27 (m, 1 H, Hα Phe), 4.13 (dt, J = 9.0, 4.6 Hz, 1 H, 
Hα Asp), 4.07 – 3.91 (m, 2 H, Hα Gly + 6-H), 3.85 (br d, J = 17.4 Hz, 1 H, 
Hα Gly), 3.63 (s, 3 H, CO2CH3 major rotamer), 3.59 (s, 3 H, CO2CH3 
minor rotamer), 3.28 – 3.19 (m, 1 H, 6-H), 3.17 – 3.03 (m, 4 H, 4-H + 
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2Hδ Arg + Hβ Phe), 2.93 (dd, J = 13.6, 9.9 Hz, 1 H, Hβ Phe), 2.53 (dd, J = 
17.1, 9.1 Hz, 1 H, Hβ Asp), 2.45 (dd, J = 16.8, 4.8 Hz, 1 H, Hβ Asp), 2.25 
– 2.11 (m, 2 H, Hγ Arg), 2.10 – 2.00 (m, 1 H, 3-H), 1.88 – 1.77 (m, 2 H, 5-
H + Hβ Arg), 1.74 (br d, J = 14.6 Hz, 1 H, Hβ Arg), 1.67 – 1.47 (m, 2 H, 3-
H + 5-H). MS (ESI) m/z (%): 660 ([M + 1]+, 100), 682 ([M + Na]+, 18). 
HRMS (ESI/TOF) m/z: [M + H]+ Calcd. for C29H41N9O9: 660.3100, Found: 
660.3089.  
(2S,4R)-4-(9-Fluorenylmethoxycarbonylamino)-1-(tert-
butyloxycarbonyl)piperidine-2-Arg(Mtr)-Gly-OBn (35): DEPBT (225 
mg, 0.75 mmol) and DIPEA (131 µL, 0.75 mmol) were added under a 
nitrogen atmosphere to a solution of 29 (174 mg, 0.37 mmol) in 
anhydrous THF (3.3 mL), cooled to 0 °C, and the resulting mixture was 
allowed to warm to room temperature. After 15 min, the reaction mixture 
was cooled again to 0 °C, and a solution of H-Arg(Mtr)-Gly-OBn (262 mg, 
0.49 mmol) in anhydrous THF (3.3 mL) was added. The ice bath was 
removed and the mixture was stirred at 35 °C (external) for 3 days. The 
mixture was then diluted with EtOAc (135 mL), washed with satd NH4Cl 
(2 × 35 mL), satd NaHCO3 (2 × 35 mL), and finally with H2O (2 × 35 mL). 
The organic extract was dried over Na2SO4, filtered, and evaporated 
under reduced pressure. The crude residue was chromatographed 
(MeOH/CH2Cl2 1:20, Rf 0.30) to give compound 35 (256 mg, 70%) as a 
white gummy solid. 1H NMR (400 MHz, CDCl3) δ (ppm): 7.78 – 7.64 (m, 
2 H), 7.64 – 7.43 (m, 2 H), 7.44 – 7.25 (m, 10 H), 6.51 (s, 1 H), 6.35 – 
6.15 (m, 2 H), 5.15 – 5.00 (m, 2 H), 4.80 – 4.43 (m, 3 H), 4.35 – 4.20 (m, 
1 H), 4.20 – 4.06 (m, 2 H), 4.01 – 3.84 (m, 2 H), 3.81 (s, 3 H), 3.47 – 3.03 
(m, 3 H), 2.67 (s, 3 H), 2.60 (s, 3 H), 2.18 (d, J = 12.9 Hz, 1 H), 2.11 (s, 3 
H), 2.02 – 1.83 (m, 2 H), 1.72 – 1.48 (m, 5 H), 1.51 – 1.29 (m, 9 H). 
MS/MS (ESI) [M + Na]+ m/z (%): 1004 ([M + Na]+, 6), 948 (18), 904 (100). 
(–)-(2S,4R)-4-[Z-Asp(OtBu)]-1-(tert-butyloxycarbonyl)-4-APA-2-
Arg(Mtr)-Gly-OBn (37): Compound 35 (256 mg, 0.26 mmol) was 
dissolved in a 1 : 1 CH2Cl2/diethylamine mixture (4.3 mL) under a 
nitrogen atmosphere. The resulting solution was stirred at room 
temperature for 4 h, meanwhile an additional 1 : 1 CH2Cl2/diethylamine 
mixture (2 mL) was added. The solution was concentrated under reduced 
pressure, the residue was taken up in CH2Cl2 (4 mL) and then 
concentrated again. The crude 36 was obtained as a pale yellow solid 
and used for the next step without further purifications. DEPBT (204 mg, 
0.68 mmol) and DIPEA (119 µL, 0.68 mmol) were added under nitrogen 
atmosphere to a solution of Z-Asp(OtBu)-OH (116 mg, 0.34 mmol) in 
anhydrous THF (3 mL), cooled at 0 °C, and the resulting mixture was 
allowed to warm to room temperature. After 15 min, this solution was 
slowly added to a solution of compound 36 in anhydrous THF (1 mL), 
precooled to 0 °C. The ice bath was removed and the resulting mixture 
was stirred at 35 °C. After 24 h, a second portion of Z-Asp(OtBu)-OH (45 
mg, 0.13 mmol), DEPBT (78 mg, 0.26 mmol) and DIPEA (46 µL, 0.26 
mmol) was added and the mixture was stirred at 35 °C for an additional 3 
days. The mixture was then diluted with EtOAc (40 mL) and washed with 
satd NH4Cl (2 × 12 mL), satd NaHCO3 (2 × 12 mL) and finally H2O (2 × 
12 mL). The organic layer was dried over Na2SO4, filtered and 
evaporated under reduced pressure. The crude residue was purified by 
flash chromatography (MeOH/CH2Cl2 1:20, Rf 0.12) and pure 37 (214 mg, 
77%) was obtained as a white solid. m.p. = 56.4 – 63.0 °C. [α]D
20 –27.8 
(c 0.97, CHCl3). 
1H NMR (400 MHz, CDCl3) (1 : 1 mixture of rotamers) δ 
(ppm): 7.45 – 7.25 (m, 10 H), 6.50 (s, 1 H), 6.42 – 6.16 (m, 2 H), 5.17 – 
5.02 (m, 4 H), 4.81 – 4.61 (m, 1 H), 4.61 – 4.39 (m, 1 H), 4.28 – 4.21 (m, 
1 H), 4.15 – 4.05 (m, 2 H), 3.98 – 3.89 (m, 1 H), 3.80 (s, 3 H), 3.37 – 3.10 
(m, 2 H), 3.02 – 2.85 (m, 1 H), 2.80 – 2.65 (m, 1 H), 2.66 (s, 3 H), 2.59 (s, 
3 H), 2.23 – 1.74 (m, 5 H), 2.11 (s, 3 H), 1.68 – 1.50 (m, 5 H), 1.43 (s, 9 
H), 1.39 (s, 9 H, one rotamer), 1.37 (s, 9 H, one rotamer). 13C NMR 
(100.4 MHz, CDCl3) (mixture of rotamers) δ (ppm): 173.1, 172.1, 171.7, 
170.9, 170.5, 169.7, 158.3, 156.5, 138.4, 136.4, 135.1, 133.3, 128.5, 
128.4, 128.3, 128.2, 128.17, 128.16, 128.0, 127.7, 124.7, 124.6, 111.6, 
81.8, 80.6, 66.9, 65.2, 63.8 and 63.7, 55.3, 52.5, 51.6, 50.8, 41.1, 40.4, 
37.9, 37.2, 28.2, 27.9 and 27.8, 24.6, 24.1, 20.3, 18.3, 15.9, 11.9. MS 
(ESI) m/z (%): 1087 ([M + Na]+, 100). HRMS (ESI/TOF) m/z: [M + Na]+ 
Calcd. for C52H72N8O14SNa: 1087.4781. Found: 1087.4743. 
(+)-Cyclo{Arg-Gly-Asp-4-APA}·TFA (39): To a solution of 37 (180 mg, 
0.17 mmol) in ethanol (14.3 mL), 10% Pd/C (117 mg, 0.11 mmol) was 
added under a nitrogen atmosphere. The resulting suspension was first 
flushed with hydrogen under vigorous stirring and then maintained under 
a hydrogen atmosphere (balloon) at room temperature. After 21 h, the 
mixture was filtered over a Celite pad and the residual solution was 
evaporated under reduced pressure. Compound 38 (139 mg, 97%) was 
obtained as a white solid and used in the next step without further 
purifications. MS (ESI) m/z (%): 845 ([M - H2O + Na]
+, 100). The crude 38 
(139 mg, 0.17 mmol) was suspended in THF (50 mL) under a nitrogen 
atmosphere. The suspension was cooled to 0 °C, and DEPBT (153 mg, 
0.51 mmol) and DIPEA (89 µL, 0.51 mmol) were added. The resulting 
mixture was stirred at 35 °C for 4 days and the diluted with EtOAc (25 
mL) and washed with satd NH4Cl (2 × 10 mL), satd NaHCO3 (2 × 10 mL), 
H2O (2 × 10 mL) and finally dried over Na2SO4. After filtration and 
evaporation of the solvent, the residue was purified by flash 
chromatography (MeOH/CH2Cl2 1:20, Rf 0.10). Cromatography column 
was then washed with MeOH. The MeOH solution was concentrated, 
taken up in CHCl3 and washed with water (3 x 15 mL) and finally 
concentrated again. The cyclopeptide was obtained as a white solid (62 
mg, 48%). MS (ESI) m/z (%): 845 ([M + Na]+, 100). The crude cyclic 
tetrapeptide was dissolved in a 95:2,5:2,5 trifluoroacetic 
acid/triisopropylsilane/H2O mixture (4,1 mL) and the resulting solution 
was stirred at room temperature for 23 h. The mixture was concentrated 
under reduced pressure, and the residue was taken up in H2O (5 mL) 
and washed with Et2O (4 × 6 mL). The aqueous layer was then 
concentrated under reduced pressure to afford the deprotected cyclic 
tetrapeptide as a trifluoroacetate salt. This crude was purified by semi-
preparative HPLC (Rt = 12.29 min) and pure 39 (10 mg, 12% over two 
steps) was obtained as a glassy solid by lyophilisation of the HPLC 
sample and the purity of the final compound was checked by analytical 
HPLC. [α]D
26 +20.3 (c 0.20, H2O). 
1H NMR (500 MHz, D2O/H2O 1:9) δ 
(ppm): 9.02 (t, J = 6.5 Hz, 1 H, NH Gly), 8.97 (d, J = 5.0 Hz, 1 H, NH Arg), 
8.19 (d, J = 9.5 Hz, 1 H, NH Asp), 7.26 (d, J = 7.5 Hz, 1 H, NH 4-APA), 
7.11 (m, 1 H, 4-NH), 6.58 (m, 5 H, NHε Arg), 4.66 (m, 2 H, Hα Asp + 2-H), 
4.20 – 4.16 (m, 1 H, Hα Gly), 4.15 – 4.10 (m, 2 H, Hα Arg + 4-H), 3.83 (td, 
J = 13.5, 3.0 Hz, 1 H, 6 H), 3.48 – 3.42 (m, 1 H, Hα Gly), 3.23 – 3.17 (m, 
1 H, 6-H'), 3.16 – 3.10 (m, 2 H, Hδ Arg), 2.85 – 2.73 (m, 2 H, Hβ Asp), 
2.40 – 2.34 (m, 1 H, 3-H), 2.14 (d, J = 16.0 Hz, 1 H, 3-H'), 1.99 – 1.93 (m, 
1 H, 5-H), 1.91 – 1.83 (m, 1 H, 5-H'), 1.74 – 1.67 (m, 2 H, Hβ Arg), 1.65 – 
1.57 (m, 1 H, Hγ Arg), 1.55 – 1.46 (m, 1 H, Hγ Arg).
 13C NMR (100.4 MHz, 
CDCl3) δ (ppm): 178.2, 177.6, 174.4, 174.3, 173.9, 159.6, 57.5, 52.3, 
51.8, 51.7, 47.1, 43.3, 43.2, 39.6, 30.5, 29.0, 27.5, 27.0. MS ESI m/z (%): 
455 ([M + 1]+, 100). HRMS (ESI/TOF) m/z: [M + H]+ Calcd. for 
C18H30N8O6: 455.2361. Found: 455.2363.  
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A stereodivergent preparation of cis and trans 4-aminopipecolic acids (4-APAs) was developed from a common precursor to obtain 
suitably protected, constrained γ-amino acids useful in peptidomimetic synthesis. Two antagonists of αVβ3 integrin were synthesized.    
